Proactive Investors - Run By Investors For Investors

Orgenesis kicks off US expansion of MaSTherCell Global subsidiary with Houston facility

It has executed a lease agreement to build a new 30,000 square feet manufacturing facility in Houston
A researcher in a lab
The Maryland-based company’s subsidiary MaSTherCell Global is a leading cell and gene therapy global contract development and manufacturing organization

Orgenesis Inc (NASDAQ:ORGS) said Friday its subsidiary MaSTherCell Global Inc is expanding into the US and building a new 30,000 square feet manufacturing facility in Houston. 

The Germantown, Maryland-based company’s subsidiary MaSTherCell Global is a leading cell and gene therapy global contract development and manufacturing organization, or CDMO.

READ: Orgenesis subsidiary Masthercell Global unveils new production wing at Belgian plant

With the US expansion, the company, which develops advanced cell therapies, will now have manufacturing facilities in three continents spanning North America, Europe and Asia

MaSTherCell is also backed by Great Point Partners LLC, a healthcare investment firm based in Greenwich, Connecticut.

In July, MaSTherCell announces a planned investment for MaSTherCell Global of up to $25 million to develop its global services through a strategic partnership between Orgenesis and Great Point Partners. According to the terms of the agreement, MaSTherCell would receive an initial upfront payment of $11.8 million, with the balance subject to achieving certain specified EBITDA and revenue targets.

The company said MaSTherCell has received the first milestone payment of $6.6 million as a result of its strategic partnership with Great Point Partners.

“We are thrilled with the performance of MaSTherCell Global since the Great Point Partners investment, and this latest tranche of funding will help drive additional growth,” said Orgenesis CEO Vered Caplan in a statement. “The additional capacity provided by this expansion should allow us to expand our presence in North America and enhance the services for our customers in order to fully capitalize on the growing global market demand.”

Through its MaSTherCell subsidiary, Orgenesis works with cell therapy organizations and drug makers to provide business modeling as well as help with manufacturing and technology selection in a bid to speed up the arrival of their therapies to the market.

The additional funding through Great Point Partners will be ploughed into launching the new US facility, and expanding the facilities in Europe, Israel, and Korea.

“The new US facility will enable new and existing clients to work with MaSTherCell across the world. MaSTherCell Global’s international reach will allow for more innovation and efficient processes, while ensuring the same quality standards across the company,” said Noah Rhodes, managing director at MaSTherCell.

Orgenesis stock opened flat at $4.69.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use